Alcohol Use Disorder Treatment Market

Alcohol Use Disorder Treatment Market Size, Market Forecast and Outlook By FMI

Summary of the Alcohol Use Disorder Treatment Market

• Demand and Growth Drivers
  • Medical recognition of alcohol use disorder as a chronic condition is increasing medication prescribing rates.
  • Extended-release formulations are improving treatment compliance.
  • Primary care screening integration is expanding early case identification.
• Product and Segment View
  • Alcohol dependence is expected to lead with 34.9% of disorder type demand in 2026.
  • Medication-based treatment is expected to represent 47.6% of treatment type demand.
  • Naltrexone is expected to account for 36.8% of drug class demand.
• Geography and Competitive Outlook
  • The USA (6.9%) is expected to lead growth, driven by high prevalence and expanding insurance coverage.
  • The EU (6.5%) maintains strong growth through standardized treatment guidelines.
  • Companies with branded extended-release formulations and addiction treatment distribution networks are expected to maintain advantages.
• Analyst Opinion
  • The alcohol use disorder treatment market is evolving from a counseling-dominated treatment model into a pharmaceutical-integrated management approach.
  • Adoption of medication-assisted treatment is increasing as clinical evidence and insurance coverage support prescribing.
  • The market is benefiting from primary care integration that improves early identification and treatment referral.
  • Companies combining extended-release formulations with adherence support programs are expected to strengthen positions.

Key Takeaways, Market Size, and Forecast

• The alcohol use disorder treatment market was valued at USD 790.0 million in 2025.
• The market is set to reach USD 838.2 million by 2026-end and grow at a CAGR of 6.1% between 2026–2036 to reach USD 1,515.3 million by 2036.
• Alcohol Dependence will dominate with a 34.9% share, while Medication will lead with a 47.6% share.
• The alcohol use disorder treatment market was valued at USD 790.00 million in 2025.
• By 2036, the Alcohol Use Disorder Treatment Market is expected to be worth USD 1515.29 million.
• From 2026 to 2036, the market is projected to expand at a CAGR of 6.1%.
• The market is projected to create an incremental opportunity of USD 677.10 million between 2026 and 2036.
• In 2026, alcohol dependence is expected to account for 34.9% of the disorder type segment, driven by sustained demand from chronic dependence management, established clinical evidence for relapse prevention, and growing integration into treatment protocols.
• USA (6.9%) and EU (6.5%) are two of the fastest growing markets in the world.

Alcohol Use Disorder Treatment Market Definition

The alcohol use disorder treatment market covers pharmaceutical and therapeutic interventions used in managing alcohol dependence and alcohol abuse, including medications such as naltrexone, acamprosate, and disulfiram, along with behavioral therapy and rehabilitation services distributed through hospitals, clinics, rehabilitation centres, and pharmacy channels.

Alcohol Use Disorder Treatment Market Inclusions

Market scope covers all commercially available alcohol use disorder treatments categorized by disorder type (alcohol dependence, alcohol abuse), treatment type (medication, behavioral therapy, combination), drug class (naltrexone, acamprosate, disulfiram, others), and distribution channel (rehabilitation centres, hospitals, retail pharmacies, online pharmacies). Revenue coverage spans 2026 to 2036.

Alcohol Use Disorder Treatment Market Exclusions

The scope does not include recreational alcohol products, alcohol testing and screening services, or detoxification services provided independently of ongoing treatment programs.

Alcohol Use Disorder Treatment Market Research Methodology

• Primary Research: FMI analysts conducted interviews with addiction medicine specialists, hospital pharmacy directors, and rehabilitation centre program managers across key markets.
• Desk Research: Combined data from pharmaceutical prescription databases, substance abuse treatment facility records, and public health surveillance reports.
• Market Sizing and Forecasting: Bottom-up sizing across disorder type, drug class, and distribution channel segments with regional treatment access curves.
• Data Validation: Cross-checked quarterly against prescription data, treatment facility utilization records, and government substance abuse spending reports.

Why is the Alcohol Use Disorder Treatment Market Growing?

• Growing clinical recognition of alcohol use disorder as a chronic medical condition requiring pharmaceutical management is increasing medication prescribing rates beyond traditional counseling-only approaches.
• Regulatory approval and insurance coverage expansion for medication-assisted treatment is reducing access barriers and increasing treatment initiation rates across healthcare systems.
• Integration of alcohol use disorder screening into primary care workflows is improving early identification and referral to treatment, expanding the diagnosed patient population.

Demand for alcohol use disorder treatment reflects the growing medical recognition of alcohol dependence as a chronic condition requiring sustained pharmaceutical intervention alongside behavioral therapy. The shift from viewing alcohol dependence as solely a behavioral issue to recognizing it as a medical condition with pharmacological treatment options is a structural demand driver that increases medication prescribing rates.

Adoption of naltrexone leads the drug class segment at 36.8%, supported by clinical evidence demonstrating efficacy in reducing heavy drinking days and supporting abstinence maintenance. Extended-release injectable naltrexone formulations have improved treatment compliance by reducing the daily oral medication burden.

Pricing reflects the mix of generic oral formulations and branded extended-release injectable products. Generic naltrexone and acamprosate provide cost-accessible base treatment options, while branded extended-release formulations command premium pricing supported by compliance and efficacy advantages.

Market Segmentation Analysis

• Alcohol Dependence accounts for 34.9% of the disorder type segment.
• Medication represents 47.6% of the treatment type segment.
• Naltrexone leads the drug class segment with 36.8% share.

The alcohol use disorder treatment market is segmented by disorder type, treatment type, drug class, and distribution channel.

Insights into the Alcohol Dependence Disorder Type Segment

Alcohol dependence represents 34.9% of disorder type demand, reflecting the chronic nature of the condition and the sustained treatment duration required for relapse prevention. Medication-assisted treatment protocols for dependence typically extend 6 to 12 months or longer.

Insights into the Medication Treatment Type Segment

Medication-based treatment represents 47.6% of treatment type demand, driven by growing prescribing adoption of naltrexone, acamprosate, and disulfiram in alcohol use disorder management protocols alongside behavioral therapy components.

Alcohol Use Disorder Treatment Market Drivers, Restraints, and Opportunities

• Regulatory and structural demand drivers are creating sustained procurement patterns.
• Cost and access constraints create segmentation in adoption rates.
• Technology and product development are expanding the addressable market.

The alcohol use disorder treatment market is shaped by regulatory, technology, and procurement dynamics.

Medical Model Adoption for Alcohol Dependence

Demand is shaped by the shift toward recognizing alcohol use disorder as a chronic medical condition with pharmacological treatment options. This medical model increases medication prescribing and insurance coverage for pharmaceutical interventions.

Extended-Release Formulation Availability

Growth reflects the availability of extended-release injectable naltrexone that improves treatment compliance by reducing the daily medication burden. Monthly injection schedules simplify treatment adherence relative to daily oral dosing.

Primary Care Screening Integration

Adoption is increasing as alcohol use disorder screening becomes integrated into routine primary care assessments. Earlier identification through AUDIT and CAGE screening tools increases referral to medication-assisted treatment.

Stigma and Treatment Access Barriers

Despite improving clinical recognition, stigma associated with alcohol dependence continues to limit treatment-seeking behavior. Treatment access barriers including cost, availability of addiction medicine specialists, and insurance coverage gaps constrain market penetration.

Analysis of Alcohol Use Disorder Treatment Market By Key Countries

Country	CAGR
USA	6.9%
EU	6.5%
South Korea	6.4%
Japan	6.3%
UK	6.2%

• USA leads with 6.9% CAGR.
• EU at 6.5% reflects expanding capabilities.
• South Korea (6.4%) and Japan (6.3%) maintain steady growth.

The global alcohol use disorder treatment market is expected to grow at 6.1% per year from 2026 to 2036.

Demand Outlook for Alcohol Use Disorder Treatment Market in the United States

The USA is expected to grow at 6.9% through 2036, driven by high alcohol use disorder prevalence, expanding insurance coverage for medication-assisted treatment, and growing integration of addiction medicine into primary care.

• High prevalence sustains substantial treatment demand.
• Insurance coverage expansion supports medication-assisted treatment access.
• Primary care integration improves early identification and referral.

Future Outlook for Alcohol Use Disorder Treatment Market in the European Union

The EU is expected to grow at 6.5% through 2036, supported by standardized treatment guidelines, public health alcohol reduction programs, and expanding access to medication-assisted treatment across member states.

• Standardized treatment guidelines support consistent prescribing.
• Public health programs increase treatment awareness and access.
• Medication-assisted treatment access is expanding.

Opportunity Analysis of Alcohol Use Disorder Treatment Market in South Korea

South Korea is expected to grow at 6.3% through 2036, supported by growing awareness of alcohol use disorder as a medical condition, expanding treatment infrastructure, and government health insurance coverage.

• Growing medical awareness increases treatment-seeking behavior.
• Treatment infrastructure expansion improves access.
• Health insurance coverage supports medication costs.

Sales Analysis of Alcohol Use Disorder Treatment Market in Japan

Japan is expected to grow at 5.8% through 2036, supported by growing recognition of alcohol dependence as a treatable medical condition, expanding addiction medicine infrastructure, and pharmaceutical treatment adoption.

• Growing medical recognition increases treatment prescribing.
• Addiction medicine infrastructure is expanding.
• Pharmaceutical treatment adoption is increasing.

In-depth Analysis of Alcohol Use Disorder Treatment Market in the United Kingdom

The UK is expected to grow at 6.2% through 2036, driven by NHS alcohol treatment programs, NICE clinical guidelines for medication-assisted treatment, and expanding community-based treatment services.

• NHS alcohol treatment programs provide structured access.
• NICE guidelines support medication prescribing adoption.
• Community-based services expand treatment reach.

Competitive Landscape and Strategic Positioning

• Alkermes plc leads with an estimated 16.2% market share.
• The competitive landscape includes global and specialized players.
• Entry barriers include regulatory, relationship, and scale factors.

Alkermes plc leads the market through Vivitrol (extended-release naltrexone), the leading branded injectable formulation for alcohol dependence management.

Pfizer Inc. and Novartis AG maintain positions through generic and branded pharmaceutical portfolios that include oral naltrexone and acamprosate formulations.

Teva Pharmaceutical Industries Ltd. and Indivior PLC compete on generic naltrexone formulations and specialized addiction treatment products respectively.

Entry barriers include the established prescribing patterns for approved medications, the clinical trial requirements for new addiction treatment drugs, and the specialized distribution channels serving rehabilitation and addiction treatment facilities.

Key Companies in the Alcohol Use Disorder Treatment Market

Key global companies leading the alcohol use disorder treatment market include:

• Alkermes plc (Ireland), Pfizer Inc. (USA), and Novartis AG (Switzerland) hold leading positions through branded injectable and generic oral formulations.
• Teva Pharmaceutical Industries Ltd. (Israel) and Indivior PLC (UK) compete on generic naltrexone and specialized addiction treatment products.
• Mylan (USA), Amneal Pharmaceuticals (USA), and Ethypharm (France) represent additional positions through generic formulations and regional distribution.

Competitive Benchmarking: Alcohol Use Disorder Treatment Market

Company	Drug Portfolio	Clinical Evidence	Distribution Network	Geographic Reach
Alkermes plc	Medium	Strong	Moderate	N. America, Europe
Pfizer Inc.	High	Strong	Strong	Global
Novartis AG	High	Strong	Strong	Global
Teva Pharmaceutical Industries	Medium	Moderate	Strong	Global
Indivior PLC	Medium	Strong	Moderate	N. America, Europe
Mylan	Medium	Moderate	Strong	Global

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Alcohol Use Disorder Treatment Market

• In 2025, Alkermes plc continued to support the use of Vivitrol in alcohol use disorder treatment, with increasing emphasis on patient support initiatives and digital tools aimed at improving treatment adherence and continuity of care.
• In 2025, Indivior PLC continued to advance long-acting and adherence-focused therapeutic approaches within addiction medicine, reflecting ongoing development efforts to improve treatment persistence and outcomes in alcohol use disorder management.

Key Players in the Alcohol Use Disorder Treatment Market

Major Global Players

• Alkermes plc
• Pfizer Inc.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Indivior PLC
• Otsuka Pharmaceutical Co., Ltd.
• Eli Lilly and Company

Emerging Players/Startups

• Mylan
• Amneal Pharmaceuticals
• Ethypharm
• Orexo AB
• Adial Pharmaceuticals

Report Scope and Coverage

Parameter	Details
Quantitative Units	USD 838.19 million to USD 1515.29 million, at a CAGR of 6.1%
Market Definition	The alcohol use disorder treatment market covers pharmaceutical and therapeutic interventions used in managing alcohol dependence and alcohol abuse, including medications such as naltrexone, acamprosate, and disulfiram, along with behavioral therapy and rehabilitation services distributed through hospitals, clinics, rehabilitation centres, and pharmacy channels.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	USA, UK, France, Germany, Italy, South Korea, Japan, China, India, 30 plus countries
Key Companies Profiled	Alkermes plc, Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Indivior PLC, Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, AbbVie Inc., Braeburn Pharmaceuticals, H. Lundbeck A/S
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions.

Market Segmentation Analysis

Alcohol Use Disorder Treatment Segmented by Disorder Type:

• Alcohol Dependence
• Alcohol Abuse
• Alcohol Addiction
• Alcoholism

Alcohol Use Disorder Treatment Segmented by Treatment Type:

• Medication
• Therapy
• Multidisciplinary Treatment

Alcohol Use Disorder Treatment Segmented by Drug Class:

• Naltrexone
• Acamprosate
• Disulfiram
• Nalmefene

Alcohol Use Disorder Treatment Segmented by Distribution Channel:

• Rehabilitation Centers
• Hospitals
• Outpatient Clinics
• Online Platforms

Alcohol Use Disorder Treatment by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• 1. National Institute on Alcohol Abuse and Alcoholism. (2025). NIAAA Treatment Guidelines: Alcohol Use Disorder Medications. NIAAA.
• 2. Substance Abuse and Mental Health Services Administration. (2024). SAMHSA National Survey on Drug Use and Health. SAMHSA.
• 3. World Health Organization. (2025). WHO Global Status Report on Alcohol and Health. WHO.
• 4. European Medicines Agency. (2024). EMA Assessment Reports: Alcohol Dependence Treatment Products. EMA.
• 5. National Institute for Health and Care Excellence. (2025). NICE Clinical Guidelines: Alcohol Use Disorders. NICE.

This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.

This Report Answers

• Estimating the market size and revenue from 2026 to 2036.
• Segmentation by disorder type, treatment type, drug class, and distribution channel.
• Regional and country-level insights across more than 30 markets.
• Treatment protocol and prescribing pattern analysis.
• Competitive landscape assessment.
• Investment opportunity identification across pharmaceutical and rehabilitation segments.
• Insurance coverage and reimbursement analysis.
• Data delivery in PDF and Excel formats.